阴性乳腺癌-话题@MedSci

#阴性乳腺癌#

226篇内容 | 3203人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2048115, encodeId=39b82048115c1, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案, objectType=article, longId=733030, objectId=73fbe3303097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73fbe3303097, replyNumber=0, likeNumber=111, createdTime=2022-09-17, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73fbe3303097, moduleTitle=Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73fbe3303097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048116, encodeId=2f872048116b2, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后, objectType=article, longId=728384, objectId=e24ae28384d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e24ae28384d8, replyNumber=0, likeNumber=89, createdTime=2023-02-13, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e24ae28384d8, moduleTitle=2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e24ae28384d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048113, encodeId=eb3920481136d, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=2022 ASCO：多西他赛和环磷酰胺辅助治疗HER2阴性乳腺癌的现实经验, objectType=article, longId=728385, objectId=dc7ae283851f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc7ae283851f, replyNumber=0, likeNumber=92, createdTime=2023-01-11, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc7ae283851f, moduleTitle=2022 ASCO：多西他赛和环磷酰胺辅助治疗HER2阴性乳腺癌的现实经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc7ae283851f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048108, encodeId=936020481085c, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Mol Cancer：新型生物标志物SNORD33可预测三阴性乳腺癌对铂类化疗敏感性, objectType=article, longId=300796, objectId=4279300e9651, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4279300e9651, replyNumber=0, likeNumber=74, createdTime=2022-08-17, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4279300e9651, moduleTitle=Mol Cancer：新型生物标志物SNORD33可预测三阴性乳腺癌对铂类化疗敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4279300e9651)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048105, encodeId=44ae2048105a6, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=NEJM：手术前后加用派姆单抗可显著提高早期三阴性乳腺癌的生存率, objectType=article, longId=295536, objectId=2e43295536c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e43295536c6, replyNumber=0, likeNumber=79, createdTime=2022-02-15, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e43295536c6, moduleTitle=NEJM：手术前后加用派姆单抗可显著提高早期三阴性乳腺癌的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e43295536c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048111, encodeId=053f2048111c4, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌, objectType=article, longId=723589, objectId=d350e23589a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d350e23589a7, replyNumber=0, likeNumber=109, createdTime=2023-03-07, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d350e23589a7, moduleTitle=Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d350e23589a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048114, encodeId=4454204811425, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后, objectType=article, longId=731076, objectId=fee6e3107677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fee6e3107677, replyNumber=0, likeNumber=0, createdTime=2022-09-30, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fee6e3107677, moduleTitle=Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fee6e3107677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048103, encodeId=deb6204810378, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, objectType=article, longId=294716, objectId=db94294e16ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db94294e16ed, replyNumber=0, likeNumber=94, createdTime=2022-04-17, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db94294e16ed, moduleTitle=J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db94294e16ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048117, encodeId=1bd0204811ef8, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=工程化肿瘤细胞载药系统治疗三阴性乳腺癌肺转移, objectType=article, longId=733415, objectId=bbd5e33415f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbd5e33415f4, replyNumber=0, likeNumber=68, createdTime=2023-01-16, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbd5e33415f4, moduleTitle=工程化肿瘤细胞载药系统治疗三阴性乳腺癌肺转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbd5e33415f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048104, encodeId=84522048104d9, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cell Research：“高危”三阴性乳腺癌有望增添代谢治疗靶点，“复旦肿瘤”科学家绘制出很大三阴性乳腺癌代谢物图谱, objectType=article, longId=295143, objectId=43a629514382, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43a629514382, replyNumber=0, likeNumber=84, createdTime=2022-04-21, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43a629514382, moduleTitle=Cell Research：“高危”三阴性乳腺癌有望增添代谢治疗靶点，“复旦肿瘤”科学家绘制出很大三阴性乳腺癌代谢物图谱, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43a629514382)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048102, encodeId=5ca6204810221, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效, objectType=article, longId=293430, objectId=627129343025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=627129343025, replyNumber=0, likeNumber=101, createdTime=2022-04-01, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=627129343025, moduleTitle=Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=627129343025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048118, encodeId=f42d2048118f2, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！, objectType=article, longId=737158, objectId=579ee371587c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=579ee371587c, replyNumber=0, likeNumber=93, createdTime=2023-05-25, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=579ee371587c, moduleTitle=Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=579ee371587c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048101, encodeId=2bb6204810154, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究, objectType=article, longId=292393, objectId=a3232923933c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3232923933c, replyNumber=0, likeNumber=94, createdTime=2022-11-15, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3232923933c, moduleTitle=Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3232923933c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048107, encodeId=792e204810e1c, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=PNAS：D-甘露糖通过降解PD-L1促进三阴性乳腺癌的免疫治疗和放疗, objectType=article, longId=300793, objectId=c77e300e932f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c77e300e932f, replyNumber=0, likeNumber=121, createdTime=2022-07-04, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c77e300e932f, moduleTitle=PNAS：D-甘露糖通过降解PD-L1促进三阴性乳腺癌的免疫治疗和放疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c77e300e932f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048109, encodeId=0b59204810950, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌, objectType=article, longId=301566, objectId=a12430156640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a12430156640, replyNumber=0, likeNumber=93, createdTime=2022-09-29, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a12430156640, moduleTitle=Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a12430156640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048110, encodeId=2c662048110f3, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Nature Cancer：免疫疗法+mRNA技术，治疗三阴性乳腺癌并防止复发, objectType=article, longId=301755, objectId=078d301e55cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=078d301e55cd, replyNumber=0, likeNumber=96, createdTime=2022-07-12, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=078d301e55cd, moduleTitle=Nature Cancer：免疫疗法+mRNA技术，治疗三阴性乳腺癌并防止复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=078d301e55cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048099, encodeId=d09d20480993b, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌, objectType=article, longId=221752, objectId=5171221e521f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5171221e521f, replyNumber=0, likeNumber=106, createdTime=2022-05-21, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5171221e521f, moduleTitle=Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5171221e521f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048106, encodeId=e385204810659, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：复旦肿瘤晚期免疫调节型三阴性乳腺癌（TNBC）新疗法，有效率高达95.8%, objectType=article, longId=300445, objectId=53d5300445da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53d5300445da, replyNumber=0, likeNumber=85, createdTime=2022-05-11, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53d5300445da, moduleTitle=Clin Cancer Res：复旦肿瘤晚期免疫调节型三阴性乳腺癌（TNBC）新疗法，有效率高达95.8%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53d5300445da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048112, encodeId=fad9204811257, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Cancer Res: 化疗联合巨噬细胞抑制三阴性乳腺癌进展, objectType=article, longId=725793, objectId=3613e257935b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3613e257935b, replyNumber=0, likeNumber=94, createdTime=2022-09-29, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3613e257935b, moduleTitle=Cancer Res: 化疗联合巨噬细胞抑制三阴性乳腺癌进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3613e257935b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2048095, encodeId=2333204809548, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：抗集落刺激因子单克隆抗体Lacnotuzumab联合吉西他滨-卡铂治疗三阴性乳腺癌的疗效, objectType=article, longId=218488, objectId=28cf21848858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28cf21848858, replyNumber=0, likeNumber=0, createdTime=2021-11-01, rootId=0, userName=circumcision, userId=f65b226, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28cf21848858, moduleTitle=Clin Cancer Res：抗集落刺激因子单克隆抗体Lacnotuzumab联合吉西他滨-卡铂治疗三阴性乳腺癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28cf21848858)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阴性乳腺癌

2020-05-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Nat Commun：复旦大学王碧芸/胡夕春团队发现转移性三阴性乳腺癌的高效联合化疗方案

2022-09-17

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

2022 ASCO：派姆单抗联合化疗可显著提高早期三阴性乳腺癌的生存预后

2023-02-13

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

2022 ASCO：多西他赛和环磷酰胺辅助治疗HER2阴性乳腺癌的现实经验

2023-01-11

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Mol Cancer：新型生物标志物SNORD33可预测三阴性乳腺癌对铂类化疗敏感性

2022-08-17

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

NEJM：手术前后加用派姆单抗可显著提高早期三阴性乳腺癌的生存率

2022-02-15

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Nature Cancer：LCOR mRNA疗法联合PD-L1抑制剂成功挑战三阴性乳腺癌

2023-03-07

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Ther Adv Med Oncol：洛铂新辅助治疗可改善三阴性乳腺癌患者预后

2022-09-30

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

J Clin Oncol：三阴性乳腺癌新辅助化疗加入卡铂或贝伐珠单抗并不能改善患者的长期预后（LTOs）

2022-04-17

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

工程化肿瘤细胞载药系统治疗三阴性乳腺癌肺转移

2023-01-16

智慧医人 (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cell Research：“高危”三阴性乳腺癌有望增添代谢治疗靶点，“复旦肿瘤”科学家绘制出很大三阴性乳腺癌代谢物图谱

2022-04-21

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效

2022-04-01

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Dato-DXd针对转移性三阴性乳腺癌的3期临床试验启动，结果令人期待！

2023-05-25

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究

2022-11-15

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

PNAS：D-甘露糖通过降解PD-L1促进三阴性乳腺癌的免疫治疗和放疗

2022-07-04

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Clin Cancer Res：法米替尼、卡瑞利珠单抗和nab-紫杉醇联合治疗晚期三阴性乳腺癌

2022-09-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Nature Cancer：免疫疗法+mRNA技术，治疗三阴性乳腺癌并防止复发

2022-07-12

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Clin Cancer Res：Lacnotuzumab联合吉西他滨-卡铂治疗晚期三阴性乳腺癌

2022-05-21

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Clin Cancer Res：复旦肿瘤晚期免疫调节型三阴性乳腺癌（TNBC）新疗法，有效率高达95.8%

2022-05-11

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Cancer Res: 化疗联合巨噬细胞抑制三阴性乳腺癌进展

2022-09-29

circumcision (审核中...)

前往app查看评论内容

#阴性乳腺癌#

Clin Cancer Res：抗集落刺激因子单克隆抗体Lacnotuzumab联合吉西他滨-卡铂治疗三阴性乳腺癌的疗效

2021-11-01

科室
- - 订阅+
  - 更多科室
工具
服务